Mr. Adrian Mendes reports

PERIMETER SCHEDULES FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL FOR MAY 28TH

Perimeter Medical Imaging AI Inc. will release its first quarter 2026 financial and operating results after market close on Thursday, May 28, 2026. Following the announcement, Perimeter management will host a webcast and conference call to discuss the results and provide a corporate update.

First quarter results conference call details

Date:  Thursday, May 28, 2026

Time:  5 p.m. Eastern Time

Dial-in numbers:  1-800-717-1738 (Canada and the United States) or 1-646-307-1865 (international)

The call will also be broadcast live and archived on the company's website.

About Perimeter Medical Imaging AI Inc.

Based in Toronto, Canada, and Dallas, Tex., Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultrahigh-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire, recently approved by the U.S. Food and Drug Administration, is the company's next-generation artificial-intelligence-enabled device. The company's ticker symbol PINK is a reference to the pink ribbons used during breast cancer awareness month.

Indications for use: The Claire OCT system is an adjunctive 3-D imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm, which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT system is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

The Claire OCT system should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multicentric disease (histologically diagnosed cancer in two different quadrants of the breast), unless in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labelling for full safety information.